Advertisement

Topics

Synergy Pharmaceuticals Reports Third Quarter 2017 Financial Results and Business Update

16:00 EST 9 Nov 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
TRULANCE® total prescription volume grew 105% Total net revenues up 117% Achieved coverage on major U.S. commercial, Medicare Part D and Managed Medicaid plans Synergy Pharmaceuticals Inc. (NASDAQ:S...

Other Sources for this Article

Synergy Pharmaceuticals Inc.
Gem Hopkins, 212-584-7610
VP, Investor Relations and Corporate Communications
ghopkins@synergypharma.com

NEXT ARTICLE

More From BioPortfolio on "Synergy Pharmaceuticals Reports Third Quarter 2017 Financial Results and Business Update"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Gastroenterology
Astroesophageal Reflux Disease (GERD) Barrett's Esophagus Celiac Disease Cholesterol Crohn's Disease Gastroenterology Hepatitis Hepatology Irritable Bowel Syndrome (IBS) Pancreatitis Peptic Ulcer Disease...